US20070224184A1 - Method for treating cellulite - Google Patents

Method for treating cellulite Download PDF

Info

Publication number
US20070224184A1
US20070224184A1 US11/703,269 US70326907A US2007224184A1 US 20070224184 A1 US20070224184 A1 US 20070224184A1 US 70326907 A US70326907 A US 70326907A US 2007224184 A1 US2007224184 A1 US 2007224184A1
Authority
US
United States
Prior art keywords
collagenase
cellulite
post
injected
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/703,269
Other languages
English (en)
Inventor
Marie Badalemente
Alexander Dagum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of State University of New York
Biospecifics Technologies LLC
Original Assignee
Research Foundation of State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of State University of New York filed Critical Research Foundation of State University of New York
Priority to US11/703,269 priority Critical patent/US20070224184A1/en
Priority to NZ570642A priority patent/NZ570642A/en
Priority to ES07751508.8T priority patent/ES2553184T3/es
Priority to BRPI0708186-3A priority patent/BRPI0708186A2/pt
Priority to PCT/US2007/004752 priority patent/WO2007100675A2/en
Priority to MX2008010767A priority patent/MX2008010767A/es
Priority to CA2643171A priority patent/CA2643171C/en
Priority to JP2008556445A priority patent/JP5775658B2/ja
Priority to KR1020087022877A priority patent/KR20080108996A/ko
Priority to AU2007221225A priority patent/AU2007221225B2/en
Priority to EP07751508.8A priority patent/EP1991258B1/en
Priority to HUE07751508A priority patent/HUE025918T2/en
Priority to SI200731702T priority patent/SI1991258T1/sl
Priority to KR1020117028099A priority patent/KR20120006063A/ko
Priority to PT77515088T priority patent/PT1991258E/pt
Priority to RS20150714A priority patent/RS54372B1/en
Priority to DK07751508.8T priority patent/DK1991258T3/en
Priority to PL07751508T priority patent/PL1991258T3/pl
Assigned to RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK reassignment RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BADALEMENTE, MARIE A., DAGUM, ALEXANDER B.
Publication of US20070224184A1 publication Critical patent/US20070224184A1/en
Priority to US12/115,256 priority patent/US7854929B2/en
Priority to IL193639A priority patent/IL193639A/en
Assigned to THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK reassignment THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAGUM, ALEXANDER B., BADALEMENTE, MARIE A.
Assigned to BIOSPECIFICS TECHNOLOGIES CORP. reassignment BIOSPECIFICS TECHNOLOGIES CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ADVANCE BIOFACTURES CORPORATION
Priority to JP2015095704A priority patent/JP2015134840A/ja
Priority to HRP20151182TT priority patent/HRP20151182T1/hr
Priority to CY20151101002T priority patent/CY1116903T1/el
Priority to US15/173,092 priority patent/US10123959B2/en
Priority to JP2016179732A priority patent/JP6498167B2/ja
Assigned to UNITED STATES PATENT AND TRADEMARK OFFICE reassignment UNITED STATES PATENT AND TRADEMARK OFFICE CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Priority to JP2018182242A priority patent/JP6649449B2/ja
Priority to US16/165,910 priority patent/US20190053995A1/en
Priority to JP2019200656A priority patent/JP6853331B2/ja
Priority to US17/727,118 priority patent/US20220249348A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Definitions

  • the invention relates to the discovery that collagenase injections are effective in lysing the collagen septae network of cellulite in humans to treat cellulite and restore a smooth skin appearance.
  • the invention related to methods of treating cellulite in a subject in need of such treatment, which involves injecting an effective amount of purified collagenase in the manufacture of a medicament to treat cellulite.
  • the collagenase is preferably purified and substantially free of other enzymes, such as proteases and/or hyaluronidase.
  • the invention related to the discovery that collagenase injections are effective in lysing the collagen septae network of cellulite in humans to treat cellulite and restore a smooth skin appearance.
  • the invention relates to methods of treating cellulite in a subject in need of such treatment, which involves injecting an effective amount of collagenase to the thigh and/or buttocks.
  • the invention also relates to the use of collagenase in the manufacture of a medicament to treat cellulite.
  • Collagenase injections have been proposed for the treatment of diseases such as Dupuytren's disease, adhesive capsulitis and Peyronie's disease. These diseases are all associated with collagen cords or plaques. (Wegman, Thomas L. U.S. Pat. No. 5,589,171 Dec. 31, 1996, U.S. Pat. No. 6,086,872 Jul. 11, 2000, U.S. Pat. No. 6,022,539, Feb. 8, 2000, Adhesive Capsulitis-patent Pending, all of which are incorporated herein by reference in their entirety).
  • Collagenase injections have also been proposed for the treatment of cellulite when combined with hyaluronidase, a soluble enzyme product prepared from mammalian testes (see Pinelle, Sheldon R. U.S. Pat. No. 4,645,668 Mar. 27, 1985).
  • the patent disclosed one working example for cellulite with a low dose of collagenase (100 units) in combination with hyaluronidase (150 units) for only in female patient. No further details in the improvement of cellulite after the injections was presented.
  • Clostridial collagenase has been shown to be clinically safe and effective in clinical trials in Dupuytren's disease in correcting the flexion contracture deformity of the hand(s). Additionally, the use of extracapsular injection of purifies Clostridial collagenase has been shown to be clinically safe and effective in the treatment of adhesive capsulitis (frozen shoulder) in clinical trials in restoring injection has also been used by others in clinical trials in Peyronie's disease, a contracture deformity of the penis.
  • Collagenase is an enzyme that has specific ability to digest collagen.
  • a preferred form of a collagenase is derived from fermentation by Clostridium histoliticum and is purified by a chromatographic technique, such as that disclosed in U.S. Application Ser. No. 60/763,470 filed on Jan. 20, 2006 (Attorney Docket Number 4024.3001 US), which is incorporated herein by reference.
  • Collagenase naturally produced by Clostridium histoliticum once purified will exhibit tow distinct peaks when run on an electrophoresis SDS gel. It is these two distinct peaks that are referred to as collagenase I and collagenase II.
  • Sterilized lyophilized collagenase powder is commercially available having a minimum assay of 50 units per mg.
  • the assay may range considerably above that from batch to batch, but is taken into account in determining the weight of the powder to use with a pharmaceutically acceptable carrier, for example, normal saline, in preparing a desired concentration for treatment.
  • the collagenase is applied in a liquid carrier that is pharmaceutically acceptable, including inertness towards the collagenase.
  • a liquid carrier that is pharmaceutically acceptable, including inertness towards the collagenase. Examples are normal saline, aqueous, NaCl/CaCl 2 buffer, aqueous dextran solution, aqueous hetastarch solution.
  • Collagenase ABC I microbial collagenases
  • Collagenase ABC II microbial collagenases
  • Collagenase ABC I is a single polypeptide chain consisting of approximately 1000 amino acids of known sequence. It has an observed molecular weight of 115 kiloDalton (kD), an isoelectric point (pI) between 5.63-5.68 and an extinction coefficient of 1.480. From its activity behavior toward synthetic substrate, it has been determined that Collagenase ABC I is the class I Clostidium histolyticum collagenase in the literature.
  • Collagenase ABC II is also a single polypeptide chain consisting of about 1000 amino acids of deduced sequence. It has an observed molecular weight of 110 kD, an isoelectric point between 5.46-5.57 and an extinction coefficient of 1.576. Collagenase ABC II functionally belongs to the class II Clostidium histolyticum collagenase in the literature.
  • the drug substance may have a 1 to 1 mass ratio for collagenase ABC-I and ABC-II with an extinction coefficient of 1.528. Both collagenases require tightly bound zinc and loosely bound calcium for their activity. Collagenase ABC I and Collagenase ABC II are not immunologically crossreactive and have a very broad hydrolyzing reactivity toward all types of collagen. Even though each collagenase shows different specificity, together they synergistic activity toward collagen.
  • Lyophilized Collagen for Injection is purified clostridial collagenase prepared as lyophilized formulation and may contain about 0.1 mg lactose monohydrate USP per 1,000 ABC units of collagenase activity.
  • a preferred collagenase composition comprises a mixture of collagenase I and collagenase II in a mass ratio of about 1 to 1 and having specific activity from about 500 SRC units/mg to about 15,000 SRC units/mg, preferably of at least about 700 SRC units/mg, more preferably of at least about 1000 SRC units/mg, even more preferably at least about 1500 SRC units/mg.
  • One SRC unit will solubilize rat tail collagen into ninhydrin reaction material equivalent to 1 nanomole of leucine per minute, at 25 degrees, C, pH 7.4. Collagenase has been described in ABC units as well.
  • the potency assay of collagenase is based on the digestion of undenatured collagen (from bovine tendon) at pH 7.2 and 37 degrees C. for 20-24 hours. The number of peptide bonds cleaved are measured by reaction with ninhydrin. Amino groups released by a solubilize digestion control are subtracted. One net ABC unit of collagenase will solubilize ninhydrin reactive material equivalent to 1.09 nanomoles of leucine per minute. One SRC unit equals approximately 6.3 ABC units.
  • the collagenase is preferably administered via injection in a liquid carrier that is pharmaceutically acceptable.
  • the carrier does not interact or deactivate the collagenase.
  • the carrier does not interact or deactivate the collagenase.
  • the carrier does not interact or deactivate the collagenase.
  • the carrier does not interact or deactivate the collagenase.
  • the carrier does not interact or deactivate the collagenase.
  • the carrier does not interact or deactivate the collagenase.
  • the carrier does not interact or deactivate the collagenase.
  • the carrier does not interact or deactivate the collagenase.
  • the carrier does not interact or deactivate the collagenase.
  • the carrier does not interact or deactivate the collagenase.
  • the lyophilized formulation can contain 0.1 mg lactose monohydrate per 1,000 ABC units.
  • Each glass vial used below contained 5,150 ABC units collagenase.
  • collagenase in a liquid carrier is injected into an area of cellulite in the subject's posterolateral thigh.
  • the amount and concentration of collagenase used is effective to lyse and dissolve the collagen septa network of the cellulite.
  • the injection is a sterile one and does not exceed 1.0 ml.
  • the total dosage is injected at five different points into the posterolateral thigh where the cellulite dimples of the thigh are most apparent.
  • the objective is to assure good distribution of the collagenase. Patients preferably rest on the contra lateral thigh, in bed, for about one, preferably two hours or more.
  • the collagenase can be administrated locally or topically, such as, a transdermal patch or topical cream or topical ointment to the area of cellulite or can be administered via an implant, such as, microcapsules or michrospheres which release collagenase over time.
  • the patient is characterized as having an area of at least 10 ⁇ 10 cm of cellulite on the posterolateral thigh.
  • the invention can achieve improvement in restoring normal and smooth skin appearance in the 10 ⁇ 10 cm are of cellulite on the posterolateral though.
  • collagenase can be administrated locally or topically, such as, a transdermal patch or topical cream or topical ointment to the area of cellulite or can be administered via an implant, such as, microcapsules or michrospheres which release collagenase over time and is administered in the absence of traimcinolone or other corticosteroids.
  • a transdermal patch or topical cream or topical ointment to the area of cellulite or can be administered via an implant, such as, microcapsules or michrospheres which release collagenase over time and is administered in the absence of traimcinolone or other corticosteroids.
  • total amount of collagenase and concentration may be repeated at 4-6 weeks intervals. Areas of cellulite, other than the posterolateral thigh may also require treatment, or repeated treatment at 4-6 week intervals. For example, the front of the thigh and the buttocks may contain areas of cellulite.
  • BMI body mass index
  • the minimum are of cellulite of the posterolateral thigh needed for inclusion was 10 ⁇ 10 cm. All patients had areas of cellulite of the posterolateral thigh which exceeds the minimum 10 ⁇ 10 cm area. Baseline digital photographs were taken of the treatment area. In a sterile fashion, 10,000 ABC units (0.58 mg) were injected at five points in the 10 ⁇ 10 cm target cellulite area. The total fluid volume of the injection was 1.0 ml. The buffer used was sterile 0.9% NaCL and 2 mM CaCl 2 . All patients are flowed post injection, at one day, one week, one, three, and six months. Post treatment photographs are taken serially.
  • Table 1 shows the results of the reduction in the cellulite in the quadrants of the thighs in the patients treated. There was significant reduction in cellulite appearance of the injected are. Cellulite are was reduced by 77% by day 1 in comparison to baseline. This result was sustained in the longer term. In comparison to baseline, cellulite area was reduced by 74% at 1 week, by 89% at 1 month, by 86% at 3 months and by 76% at 6 months.
  • Adverse events included tenderness in the injection area, ecchymosis and mild edema which resolved well in the mean of 10, 18 and 6 days respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
US11/703,269 2005-01-21 2007-02-07 Method for treating cellulite Abandoned US20070224184A1 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
US11/703,269 US20070224184A1 (en) 2006-02-22 2007-02-07 Method for treating cellulite
MX2008010767A MX2008010767A (es) 2006-02-22 2007-02-22 Metodo para tratar celulitis.
ES07751508.8T ES2553184T3 (es) 2006-02-22 2007-02-22 Colagenasa para tratar la celulitis
BRPI0708186-3A BRPI0708186A2 (pt) 2006-02-22 2007-02-22 método para tratar celulite
PCT/US2007/004752 WO2007100675A2 (en) 2006-02-22 2007-02-22 Collagenase for treating cellulite
PL07751508T PL1991258T3 (pl) 2006-02-22 2007-02-22 Kolagenaza do leczenia cellulitu
CA2643171A CA2643171C (en) 2006-02-22 2007-02-22 Collagenase for treating cellulite
JP2008556445A JP5775658B2 (ja) 2006-02-22 2007-02-22 セルライト処置用コラゲナーゼ
EP07751508.8A EP1991258B1 (en) 2006-02-22 2007-02-22 Collagenase for treating cellulite
AU2007221225A AU2007221225B2 (en) 2006-02-22 2007-02-22 Collagenase for treating cellulite
KR1020087022877A KR20080108996A (ko) 2006-02-22 2007-02-22 셀룰라이트 치료용 아교질분해효소
HUE07751508A HUE025918T2 (en) 2006-02-22 2007-02-22 Collagenase for treatment of cellulite
SI200731702T SI1991258T1 (sl) 2006-02-22 2007-02-22 Kolagenaza za zdravljenje celulita
KR1020117028099A KR20120006063A (ko) 2006-02-22 2007-02-22 셀룰라이트 치료용 아교질분해효소
PT77515088T PT1991258E (pt) 2006-02-22 2007-02-22 Colagenase para o tratamento da celulite
RS20150714A RS54372B1 (en) 2006-02-22 2007-02-22 COLLAGENASIS FOR TREATMENT OF CELLULITE
DK07751508.8T DK1991258T3 (en) 2006-02-22 2007-02-22 Collagenase for the treatment of cellulite
NZ570642A NZ570642A (en) 2006-02-22 2007-02-22 Collagenase for treating cellulite
US12/115,256 US7854929B2 (en) 2005-01-21 2008-05-05 Method for treating lateral epicondylitis using collagenase
IL193639A IL193639A (en) 2006-02-22 2008-08-21 Purified collagen for use as a cellulite treatment drug
JP2015095704A JP2015134840A (ja) 2006-02-22 2015-05-08 セルライト処置用コラゲナーゼ
HRP20151182TT HRP20151182T1 (hr) 2006-02-22 2015-11-04 Kolagenaza za tretiranje celulita
CY20151101002T CY1116903T1 (el) 2006-02-22 2015-11-10 Κολλαγοναση για θεραπευτικη αντιμετωπιση της κυτταριτιδας
US15/173,092 US10123959B2 (en) 2006-02-22 2016-06-03 Methods for treating cellulite
JP2016179732A JP6498167B2 (ja) 2006-02-22 2016-09-14 セルライト処置用コラゲナーゼ
JP2018182242A JP6649449B2 (ja) 2006-02-22 2018-09-27 セルライト処置用コラゲナーゼ
US16/165,910 US20190053995A1 (en) 2006-02-22 2018-10-19 Methods for Treating Cellulite
JP2019200656A JP6853331B2 (ja) 2006-02-22 2019-11-05 セルライト処置用コラゲナーゼ
US17/727,118 US20220249348A1 (en) 2006-02-22 2022-04-22 Methods for treating cellulite

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77569006P 2006-02-22 2006-02-22
US11/703,269 US20070224184A1 (en) 2006-02-22 2007-02-07 Method for treating cellulite

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/335,157 Continuation-In-Part US20060204488A1 (en) 2005-01-21 2006-01-19 Methods for treating adhesive capsulitis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/115,256 Continuation-In-Part US7854929B2 (en) 2005-01-21 2008-05-05 Method for treating lateral epicondylitis using collagenase
US15/173,092 Continuation US10123959B2 (en) 2006-02-22 2016-06-03 Methods for treating cellulite

Publications (1)

Publication Number Publication Date
US20070224184A1 true US20070224184A1 (en) 2007-09-27

Family

ID=38325147

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/703,269 Abandoned US20070224184A1 (en) 2005-01-21 2007-02-07 Method for treating cellulite
US15/173,092 Active US10123959B2 (en) 2006-02-22 2016-06-03 Methods for treating cellulite
US16/165,910 Abandoned US20190053995A1 (en) 2006-02-22 2018-10-19 Methods for Treating Cellulite
US17/727,118 Pending US20220249348A1 (en) 2006-02-22 2022-04-22 Methods for treating cellulite

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/173,092 Active US10123959B2 (en) 2006-02-22 2016-06-03 Methods for treating cellulite
US16/165,910 Abandoned US20190053995A1 (en) 2006-02-22 2018-10-19 Methods for Treating Cellulite
US17/727,118 Pending US20220249348A1 (en) 2006-02-22 2022-04-22 Methods for treating cellulite

Country Status (19)

Country Link
US (4) US20070224184A1 (zh)
EP (1) EP1991258B1 (zh)
JP (5) JP5775658B2 (zh)
KR (2) KR20120006063A (zh)
AU (1) AU2007221225B2 (zh)
BR (1) BRPI0708186A2 (zh)
CA (1) CA2643171C (zh)
DK (1) DK1991258T3 (zh)
ES (1) ES2553184T3 (zh)
HR (1) HRP20151182T1 (zh)
HU (1) HUE025918T2 (zh)
IL (1) IL193639A (zh)
MX (1) MX2008010767A (zh)
NZ (1) NZ570642A (zh)
PL (1) PL1991258T3 (zh)
PT (1) PT1991258E (zh)
RS (1) RS54372B1 (zh)
SI (1) SI1991258T1 (zh)
WO (1) WO2007100675A2 (zh)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123454A1 (en) * 2005-01-21 2009-05-14 Advance Biofactures Corporation Methods for treating adhesive capsulitis
US20090233885A1 (en) * 2006-07-14 2009-09-17 Duncan Diane I Compositions and Methods for Fat Reduction
WO2010102262A1 (en) 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
US7824673B2 (en) 1994-12-15 2010-11-02 Advance Biofactures Corporation Reduction of adipose tissue
WO2013059619A1 (en) 2011-10-21 2013-04-25 Auxilium Pharmaceuticals, Inc. Method of treating or reducing efp
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US9757435B2 (en) 2012-01-12 2017-09-12 Endo Global Ventures Clostridium histolyticum enzymes and methods for the use thereof
US9775889B2 (en) 2008-03-06 2017-10-03 Halozyme, Inc. Methods of treatment of cellulite
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US10117892B2 (en) 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
WO2021108751A1 (en) * 2019-11-26 2021-06-03 Standard Of Care Corporation Hyaluronidase compositions and methods of using same to treat cellulite
US11123280B2 (en) * 2017-03-01 2021-09-21 Endo Ventures Limited Method of assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
JP5284239B2 (ja) * 2009-10-07 2013-09-11 株式会社メタコ スクリーン装置
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
CA2907255C (en) 2013-03-15 2021-09-21 Biospecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
AU2019341663A1 (en) * 2018-09-18 2021-04-22 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
WO2020142701A1 (en) * 2019-01-06 2020-07-09 Endo Global Aesthetics Limited Collagenase formulations and methods of producing the same
WO2021076618A1 (en) 2019-10-15 2021-04-22 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
US20230405097A1 (en) * 2022-05-10 2023-12-21 Endo Global Aesthetics Limited Methods of reducing collagenase-mediated bruising in a subject having cellulite

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US5753485A (en) * 1994-06-24 1998-05-19 Boehringer Mannheim Corporation Purified mixture of collagenase I, collagenase II and two other proteases
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
US6086877A (en) * 1994-09-27 2000-07-11 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease
US6335388B1 (en) * 1997-10-03 2002-01-01 Lavipharm Laboratories Inc. Prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6358539B1 (en) * 1999-08-20 2002-03-19 Howard Murad Pharmaceutical compositions for reducing the appearance of cellulite
US20030129178A1 (en) * 1994-12-15 2003-07-10 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US20060204488A1 (en) * 2005-01-21 2006-09-14 Badalamente Marie A Methods for treating adhesive capsulitis
US20070224183A1 (en) * 2006-01-30 2007-09-27 Sabatino Gregory L Compositions and methods for treating collagen-mediated diseases
USRE39941E1 (en) * 1997-03-27 2007-12-18 Advance Biofactures Corporation Amelioration of Dupuytren's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5422103A (en) * 1991-11-20 1995-06-06 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5514370A (en) * 1991-11-20 1996-05-07 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
US5753485A (en) * 1994-06-24 1998-05-19 Boehringer Mannheim Corporation Purified mixture of collagenase I, collagenase II and two other proteases
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US6086877A (en) * 1994-09-27 2000-07-11 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease
US20030129178A1 (en) * 1994-12-15 2003-07-10 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
USRE39941E1 (en) * 1997-03-27 2007-12-18 Advance Biofactures Corporation Amelioration of Dupuytren's disease
US6335388B1 (en) * 1997-10-03 2002-01-01 Lavipharm Laboratories Inc. Prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
US6358539B1 (en) * 1999-08-20 2002-03-19 Howard Murad Pharmaceutical compositions for reducing the appearance of cellulite
US20060204488A1 (en) * 2005-01-21 2006-09-14 Badalamente Marie A Methods for treating adhesive capsulitis
US20070224183A1 (en) * 2006-01-30 2007-09-27 Sabatino Gregory L Compositions and methods for treating collagen-mediated diseases

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7824673B2 (en) 1994-12-15 2010-11-02 Advance Biofactures Corporation Reduction of adipose tissue
US8323643B2 (en) 2005-01-21 2012-12-04 The Research Foundation Of State University Of New York Methods for treating adhesive capsulitis
US20090123454A1 (en) * 2005-01-21 2009-05-14 Advance Biofactures Corporation Methods for treating adhesive capsulitis
US20090233885A1 (en) * 2006-07-14 2009-09-17 Duncan Diane I Compositions and Methods for Fat Reduction
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US9775889B2 (en) 2008-03-06 2017-10-03 Halozyme, Inc. Methods of treatment of cellulite
US9833498B2 (en) 2008-03-06 2017-12-05 Halozyme, Inc. Methods of treatment of collagen-mediated diseases and conditions
WO2010102262A1 (en) 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
US20100284995A1 (en) * 2009-03-06 2010-11-11 Louis Bookbinder Temperature sensitive mutants of matrix metalloproteases and uses thereof
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
AU2017248451B2 (en) * 2011-10-21 2019-11-14 Auxilium International Holdings, Inc. Method of treating or reducing efp
WO2013059619A1 (en) 2011-10-21 2013-04-25 Auxilium Pharmaceuticals, Inc. Method of treating or reducing efp
EP3581199A1 (en) 2011-10-21 2019-12-18 Endo Global Ventures Method of treating or reducing efp
US9757435B2 (en) 2012-01-12 2017-09-12 Endo Global Ventures Clostridium histolyticum enzymes and methods for the use thereof
US11879141B2 (en) 2012-01-12 2024-01-23 Endo Global Ventures Nucleic acid molecules encoding clostridium histolyticum collagenase II and methods of producing the same
US11975054B2 (en) 2012-01-12 2024-05-07 Endo Global Ventures Nucleic acid molecules encoding clostridium histolyticum collagenase I and methods of producing the same
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
US10117892B2 (en) 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
US11123280B2 (en) * 2017-03-01 2021-09-21 Endo Ventures Limited Method of assessing and treating cellulite
US11813347B2 (en) 2017-03-01 2023-11-14 Endo Ventures Limited Method of assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase
WO2021108751A1 (en) * 2019-11-26 2021-06-03 Standard Of Care Corporation Hyaluronidase compositions and methods of using same to treat cellulite

Also Published As

Publication number Publication date
AU2007221225B2 (en) 2010-02-11
JP5775658B2 (ja) 2015-09-09
BRPI0708186A2 (pt) 2011-05-24
US20190053995A1 (en) 2019-02-21
CA2643171C (en) 2018-10-02
PL1991258T3 (pl) 2016-04-29
NZ570642A (en) 2012-03-30
RS54372B1 (en) 2016-04-28
EP1991258A2 (en) 2008-11-19
EP1991258B1 (en) 2015-08-12
US20160279046A1 (en) 2016-09-29
KR20080108996A (ko) 2008-12-16
IL193639A (en) 2015-01-29
US10123959B2 (en) 2018-11-13
HUE025918T2 (en) 2016-05-30
AU2007221225A1 (en) 2007-09-07
US20220249348A1 (en) 2022-08-11
JP2009527570A (ja) 2009-07-30
JP2018199733A (ja) 2018-12-20
HRP20151182T1 (hr) 2016-01-01
JP2016204396A (ja) 2016-12-08
WO2007100675A3 (en) 2007-11-15
SI1991258T1 (sl) 2016-02-29
DK1991258T3 (en) 2015-11-16
MX2008010767A (es) 2008-09-01
JP6649449B2 (ja) 2020-02-19
JP2015134840A (ja) 2015-07-27
JP6498167B2 (ja) 2019-04-10
PT1991258E (pt) 2015-11-24
CA2643171A1 (en) 2007-09-07
IL193639A0 (en) 2011-08-01
JP2020015771A (ja) 2020-01-30
KR20120006063A (ko) 2012-01-17
WO2007100675A2 (en) 2007-09-07
ES2553184T3 (es) 2015-12-04
JP6853331B2 (ja) 2021-03-31

Similar Documents

Publication Publication Date Title
US10123959B2 (en) Methods for treating cellulite
US7854929B2 (en) Method for treating lateral epicondylitis using collagenase
CA2852942C (en) Method of treating or reducing efp
KR100989267B1 (ko) 유착 관절낭염을 치료하는 방법
US9144600B2 (en) Methods for treatment of incontinence associated with sexual activity
WO2007100590A2 (en) Methods for treating cellulite
NZ624057B2 (en) Method of treating or reducing efp

Legal Events

Date Code Title Description
AS Assignment

Owner name: RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BADALEMENTE, MARIE A.;DAGUM, ALEXANDER B.;REEL/FRAME:019426/0489

Effective date: 20070212

AS Assignment

Owner name: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BADALEMENTE, MARIE A.;DAGUM, ALEXANDER B.;REEL/FRAME:021586/0572;SIGNING DATES FROM 20080911 TO 20080915

AS Assignment

Owner name: BIOSPECIFICS TECHNOLOGIES CORP., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ADVANCE BIOFACTURES CORPORATION;REEL/FRAME:021820/0834

Effective date: 20081028

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION

AS Assignment

Owner name: UNITED STATES PATENT AND TRADEMARK OFFICE, VIRGINI

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK;REEL/FRAME:046465/0334

Effective date: 20180726